Skin Cancer Drugs Global Market Report 2023

Description

“Skin Cancer Drugs Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on skin cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for skin cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The skin cancer drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Actinic Keratoses (AK); Basal cell carcinoma (BCC); Squamous cell carcinoma (SCC); Melanoma

2) By End Users: Hospitals; Cancer Research Centers; Clinics

3) By Drug Class: Chemotherapy; Immunotherapy; Targeted Agents & Other Drugs

Companies Mentioned: Novartis AG; Bristol Myers Squibb; Eli Lilly; Meda; Sun Pharmaceutical Industries Ltd

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the skin cancer drugs market are: Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd, Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC and Pfizer Inc.

The global skin cancer drugs market will grow from $3.03 billion in 2022 to $3.41 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The skin cancer drugs market is expected to grow to $5.23 billion in 2027 at a CAGR of 11.3%.

The skin cancer drugs market consists of sales of vismodegib (Erivedge) and sonidegib (Odomzo). Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Skin cancer drugs refer to chemotherapy drugs that are used to treat skin cancer. Skin cancer refers to aberrant skin cell proliferation, which most frequently appears on sun-exposed skin. However, this prevalent type of cancer can also develop on parts of your skin that are not often exposed to sunlight. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma, or melanoma. Examples of skin cancer drugs include 5-FU, Aldara, and Efudex.

North America is the largest region in the skin cancer drugs market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the skin cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses are broad, rough skin patches that can turn cancerous. It commonly appears on sun-exposed regions such as the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents and other drugs and are used in various sectors such as hospitals, cancer research centers, and clinics.

A significant rise in the prevalence of skin cancer is driving the demand for drugs for Skin Cancer. To treat such high cases of skin cancer, more new innovative skin cancer drugs are being manufactured.in 2022, according to The American Cancer Society, a US-based organization, approximately 99,780 new melanoma skin cancer is diagnosed and approximately 7,650 people are expected to die of melanoma skin cancer every year. . This is boosting the demand for skin cancer drugs and thus driving the market.

The increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs target melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer-causing melanoma cells. Thus, doctors prefer targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward.

Companies in the Skin Cancer Market are increasingly looking for Strategic Alliances with other companies in the market. Strategic Alliance would help companies to enhance their R&D capability, expedite the development process of new drugs, and reinforce their competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies for the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug for skin cancer.

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for the safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, checking for the intended use of the drug and whether the drug is meeting the requirement of a clinical trial. EMA also educates the patients regarding the risks associated with taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, the benefits of the drug, and all other relevant information about such drugs.

In April 2022, Regeneron, a US-based biotechnology company acquired Checkmate Pharmaceuticals for $250 million. Through this acquisition, Regeneron expands its research efforts in immuno-oncology potential approaches for difficult-to-treat cancers. Checkmate Pharmaceuticals is a US-based company operating in skin cancer drugs.

The countries covered in the skin cancer drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The skin cancer drugs market research report is one of a series of new reports from The Business Research Company that provides skin cancer drugs market statistics, including skin cancer drugs industry global market size, regional shares, competitors with a skin cancer drugs market share, detailed skin cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. This skin cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Product Code: r2566

1. Executive Summary

2. Skin Cancer Drugs Market Characteristics

3. Skin Cancer Drugs Market Trends And Strategies

4. Skin Cancer Drugs Market - Macro Economic Scenario

4.1 COVID-19 Impact On Skin Cancer Drugs Market

4.2 Ukraine-Russia War Impact On Skin Cancer Drugs Market

4.3 Impact Of High Inflation On Skin Cancer Drugs Market

5. Skin Cancer Drugs Market Size And Growth

5.1. Global Skin Cancer Drugs Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global Skin Cancer Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. Skin Cancer Drugs Market Segmentation

6.1. Global Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Actinic Keratoses (AK)
Basal cell carcinoma (BCC)
Squamous cell carcinoma (SCC)
Melanoma
6.2. Global Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospitals
Cancer Research Centers
Clinics
6.3. Global Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Chemotherapy
Immunotherapy
Targeted Agents & Other Drugs

7. Skin Cancer Drugs Market Regional And Country Analysis

7.1. Global Skin Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Skin Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Skin Cancer Drugs Market

8.1. Asia-Pacific Skin Cancer Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.4. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Skin Cancer Drugs Market

9.1. China Skin Cancer Drugs Market Overview
9.2. China Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.4. China Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Skin Cancer Drugs Market

10.1. India Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.3. India Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Skin Cancer Drugs Market

11.1. Japan Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.3. Japan Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Skin Cancer Drugs Market

12.1. Australia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.3. Australia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Skin Cancer Drugs Market

13.1. Indonesia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.3. Indonesia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Skin Cancer Drugs Market

14.1. South Korea Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.3. South Korea Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Skin Cancer Drugs Market

15.1. Western Europe Skin Cancer Drugs Market Overview
15.2. Western Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.4. Western Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Skin Cancer Drugs Market

16.1. UK Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.3. UK Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Skin Cancer Drugs Market

17.1. Germany Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.3. Germany Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Skin Cancer Drugs Market

18.1. France Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.3. France Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Skin Cancer Drugs Market

19.1. Eastern Europe Skin Cancer Drugs Market Overview
19.2. Eastern Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.4. Eastern Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Skin Cancer Drugs Market

20.1. Russia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.3. Russia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Skin Cancer Drugs Market

21.1. North America Skin Cancer Drugs Market Overview
21.2. North America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.4. North America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Skin Cancer Drugs Market

22.1. USA Skin Cancer Drugs Market Overview
22.2. USA Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.4. USA Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Skin Cancer Drugs Market

23.1. South America Skin Cancer Drugs Market Overview
23.2. South America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.4. South America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Skin Cancer Drugs Market

24.1. Brazil Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.3. Brazil Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Skin Cancer Drugs Market

25.1. Middle East Skin Cancer Drugs Market Overview
25.2. Middle East Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.4. Middle East Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Skin Cancer Drugs Market

26.1. Africa Skin Cancer Drugs Market Overview
26.2. Africa Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.4. Africa Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Skin Cancer Drugs Market Competitive Landscape And Company Profiles

27.1. Skin Cancer Drugs Market Competitive Landscape
27.2. Skin Cancer Drugs Market Company Profiles
- 27.2.1. Novartis AG
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. Bristol Myers Squibb
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Eli Lilly
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. Meda
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. Sun Pharmaceutical Industries Ltd
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. Skin Cancer Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Skin Cancer Drugs Market

30. Skin Cancer Drugs Market Future Outlook and Potential Analysis

31. Appendix

31.1. Abbreviations
31.2. Currencies
31.3. Historic And Forecast Inflation Rates
31.4. Research Inquiries
31.5. The Business Research Company
31.6. Copyright And Disclaimer